Get the Stockscreener App
99.82
2.09%
2.04
After Hours:
99.50
-0.32
-0.32%
Revolution Medicines Inc stock is traded at $99.82, with a volume of 3.57M.
It is up +2.09% in the last 24 hours and up +23.62% over the past month.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.
See More
Previous Close:
$97.78
Open:
$98.135
24h Volume:
3.57M
Relative Volume:
1.08
Market Cap:
$19.30B
Revenue:
$29.52M
Net Income/Loss:
$-567.06M
P/E Ratio:
-27.27
EPS:
-3.66
Net Cash Flow:
$-551.11M
1W Performance:
-14.11%
1M Performance:
+23.62%
6M Performance:
+163.34%
1Y Performance:
+145.08%
1-Day Range:
$97.75
$101.93
1-Week Range:
$92.50
$120.63
52-Week Range:
$29.17
$124.49
Revolution Medicines Inc Stock (RVMD) Company Profile
Name
Revolution Medicines Inc
Sector
Industry
Phone
415-766-3638
Address
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
99.82 | 18.90B | 29.52M | -567.06M | -551.11M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Nov-03-25 | Initiated | RBC Capital Mkts | Outperform |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Oct-16-25 | Resumed | Stifel | Buy |
| Sep-12-25 | Resumed | Raymond James | Strong Buy |
| Sep-05-25 | Initiated | Truist | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Aug-15-25 | Initiated | Wells Fargo | Overweight |
| Jul-15-25 | Initiated | Goldman | Buy |
| Jul-16-24 | Reiterated | Needham | Buy |
| Jul-12-24 | Initiated | Barclays | Overweight |
| Jul-08-24 | Initiated | Jefferies | Buy |
| Apr-12-24 | Reiterated | Needham | Buy |
| Apr-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-04-24 | Initiated | Wedbush | Outperform |
| Nov-16-23 | Initiated | Raymond James | Outperform |
| Feb-28-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-14-22 | Initiated | Needham | Buy |
| Oct-21-22 | Initiated | Oppenheimer | Outperform |
| May-20-22 | Initiated | BofA Securities | Neutral |
| Mar-01-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Aug-12-21 | Downgrade | Goldman | Buy → Neutral |
| May-18-21 | Initiated | Goldman | Buy |
| May-21-20 | Initiated | H.C. Wainwright | Buy |
| Mar-09-20 | Initiated | Cowen | Outperform |
| Mar-09-20 | Initiated | Guggenheim | Buy |
| Mar-09-20 | Initiated | JP Morgan | Neutral |
View All
Revolution Medicines Inc Stock (RVMD) Latest News
Oppenheimer Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $150 - 富途牛牛
RVMD Stock Tumbles as MRK Reportedly Withdraws Buyout Offer - Nasdaq
Truist Financial Initiates Revolution Medicines(RVMD.US) With Buy Rating - 富途牛牛
Oppenheimer Raises Price Target for Revolution Medicines (RVMD) - GuruFocus
Revolution Medicines (RVMD) Dives 16.9% as Merck Withdraws Takeover Plan - Insider Monkey
Why Revolution Medicines stock plummeted by almost 17% today - MSN
Why Revolution Medicines Stock Plummeted by Almost 17% Today - Nasdaq
Why Revolution Medicines Stock Plummeted by Almost 17% Today - The Motley Fool
Merck stock slips after report says MRK stepped back from Revolution Medicines talks - TechStock²
MSD Reportedly Ends Takeover Talks with Revolution Medicines - marketscreener.com
Revolution Medicines (NASDAQ:RVMD) Shares Gap DownTime to Sell? - MarketBeat
Aug Chart Watch: Is Revolution Medicines Inc. stock undervalued right nowJuly 2025 Recap & AI Optimized Trade Strategies - baoquankhu1.vn
Merck Chooses Evolution Over RevolutionAt Proposed Price, I'm Not Surprised (NYSE:MRK) - Seeking Alpha
Merck, negotiations to acquire biotech Revolution Medicines stalled - Il Sole 24 ORE
Merck Ends Acquisition Talks With Revolution Medicines After Valuation Dispute - Yahoo Finance
Revolution Medicines (RVMD) Stock Plummets Over 17% - GuruFocus
Merck Walks Away: What The Failed Acquisition Means For Revolution Medicines - Seeking Alpha
Revolution Medicines Advances RMC-5127 KRAS Program, Extending Its Oncology Reach - TipRanks
Merger Arbs See Wide-Open Deal Window With Biotech Top of List - Bloomberg
CVC, Mankind, Revolution Medicines - Bloomberg.com
Revolution Medicines plummets on report Merck walks from acquisition talks - MSN
Revolution Medicines (RVMD) Sees Significant Price Drop - GuruFocus
No bid for Revolution Medicines – Merck leaves the negotiating table - Biostock
Revolution Medicines shares slide after Merck reportedly walks away from takeover talks - MSN
Revolution Medicines (RVMD) Shares Plunge as Merck Ends Acquisition Talks - GuruFocus
The $6 Billion Disconnect: Why Revolution Medicines (RVMD) Plunged 20% After Merck Talks Collapsed - FinancialContent
Revolution Medicines stock falls after Merck reportedly ends acquisition pursuit - Investing.com Australia
Revolution Medicines (RVMD) Stock Falls as Merck Walks Away From Takeover Deal - Blockonomi
Revolution Medicines, Erasca And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Pharma industry's biggest acquisition in two years could collapse - medwatch.com
Revolution Medicines (RVMD) Stock Drops After Acquisition Talks End - GuruFocus
MSD said to have pulled back from Revolution Meds deal - pharmaphorum
Merck Backs Off Revolution After Failing To Agree on Price: WSJ - BioSpace
S&P 500 Futures Decline in Premarket Trading; Revolution Medicines, UFP Industries Lag - Barron's
MSD ends takeover talks with Revolution Medicines - Yahoo Finance
Merck walks away from Revolution talks as price gap bites - The Pharma Letter
Revolution Medicines Stock Sinks After Merck Deal Talks Collapse - Benzinga
Merck Ends Talks to Acquire Revolution Medicines, WSJ Reports - Bloomberg
Revolution Medicines plunges after report Merck no longer in buyout talks - TradingView
Revolution Medicines stock dives in premarket after report Merck walked away from takeover talks - TechStock²
Revolution Medicines (RVMD) Stock Tanks as Merck Acquisition Talks End Over Price Dispute - CoinCentral
Merck (MRK) Halts Acquisition Talks with Revolution Medicines - GuruFocus
Trending tickers: USA Rare Earth, Revolution Medicines, Ryanair and Fresnillo - Yahoo Finance UK
Merck drops talks to acquire Revolution Medicines - Latest news from Azerbaijan
Revolution Medicines stock stares at big dip after Merck reportedly shelves buyout — but analyst flags opportunity - MSN
Merck no longer in talks to buy Revolution Medicines, WSJ reports - Yahoo Finance
Revolution Medicines Stock Stares At Big Dip After Merck Reportedly Shelves Buyout — But Analyst Flags Opportunity - Asianet Newsable
M&A News: Revolution Medicines (RVMD) Stock Plunges as Merck Ends Takeover Talks on Price Disagreement - TipRanks
Merck and Revolution Medicines Talks May Restart - Intellectia AI
Merck ends talks to buy Revolution Medicines, WSJ reports - MSN
Merck & Co. backs out of acquisition talks with Revolution Medicines: report - FirstWord Pharma
Revolution Medicines Inc Stock (RVMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.87%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):